Benefits of subcutaneous continuous insulin infusion in type 1 diabetic patients with high glycemic variability;Beneficios de la terapia con infusión subcutánea continua de insulina en pacientes diabéticos tipo 1 que presentan gran variabilidad glucémica

Endocrinologia y Nutricion

Volumn 59, Issue 4, 2012, Pages 246-253

  Prieto Tenreiro, Alma ^a   Villar Taibo, Rocío ^b   Pazos Couselo, Marcos ^c   González Rodríguez, María ^c   Casanueva, Felipe ^c,d   García López, José Manuel ^c  

^a HOSPITAL EL BIERZO   (Spain)

^b HOSPITAL UNIVERSITARIO DE LEÓN   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Continuous glucose monitoring; Continuous subcutaneous insulin infusion; Glucose variability; Hypoglycemia; Type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN;

ARTICLE; BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; DIABETIC PATIENT; GLYCEMIC INDEX; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIA; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 84859439120     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2012.02.005     Document Type: Article

References (42)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control, Complications Trial (DCCT) Research, Group.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
3. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and micro vascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
4. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996, 45:1289-1298. The Diabetes Control, complications Trial Research Group.
5. Cryer P.E., Davis S.N., Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003, 26:1902-1912.
6. MacLeod K.M., Hepburn D.A., Frier B.M. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 1993, 10:238-245.
7. Laing S.P., Swerdlow A.J., Slater S.D., Botha J.L., Burden A.C., Waugh N.R., et al. The British Diabetic Association Cohort Study. II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999, 16:466-471.
8. Cox D.J., Penberthy J.K., Zrebiec J., Weinger K., Aikens J.E., Frier B., et al. Diabetes and driving mishaps: frequency and correlations from a multinational survey. Diabetes Care 2003, 26:2329-2334.
9. Weissberg-Benchell J., Antisdel-Lomaglio J., Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003, 26:1079-1087.
10. Hoogma R.P., Hammond P.J., Gomis R., Kerr D., Bruttomesso D., Bouter K.P., et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med 2006, 23:141-147.
11. Retnakaran R., Hochman J., DeVries J.H., Hanaire-Broutin H., Heine R.J., Melki V., et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004, 27:2590-2596.
12. Garg S.K., Walker A.J., Hoff H.K., D'Souza A.O., Gottlieb P.A., Chase H.P. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol Ther 2004, 6:9-15.
13. Harmel A.P., Mathur R. Similar A1C outcomes in type 1 diabetic patients undergoing intensive diabetes management with preprandial rapid-acting insulin and either CSII or glargine. Diabetes Care 2004, 27:272-273.
14. Doyle E.A., Weinzimer S.A., Steffen A.T., Ahern J.A., Vincent M., Tamborlane W.V. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004, 27:1554-1558.
15. Hirsch I.B., Bode B.W., Garg S., Lane W.S., Sussman A., Hu P., et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005, 28:533-538.
16. Continuous subcutaneous insulin infusion. Diabetes Care 2004, 27:110. American Diabetes Association.
17. NICE Guidance on the use of continuous subcutaneous insulina infusion for diabetes. Technology appraisal guidance no. 57 2003, National Institute for Clinical Excellence, London.
18. DeVries J.H., Snoek F.J., Kostense P.J., Masurel N., Heine R.J. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 2002, 25:2074-2080. Dutch Insulin Pump Study Group.
19. Pickup J.C., Sutton A.J. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008, 25:765-774.
20. Schiaffini R., Ciampalini P., Spera S., Cappa M., Crino A. An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes. Diab Metab Res Rev 2005, 21:347-352.
21. Bruttomesso D., Crazzolara D., Maran A., Costa S., Dal Pos M., Girelli A., et al. In type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med 2008, 25:326-332.
22. Hanaire-Broutin H., Melki V., Bessieres-Lacombe S., Tauber J.P. Comparison of continuous subcutaneous insulina infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. Diabetes Care 2000, 23:1232-1235.
23. Oduneye F. Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes. STEER: Succinct and Timely Evaluated Evidence Reviews 2002, 2:1-8. Bazian Ltd, London.
24. Monami M., Lamanna C., Marchionni N., Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol 2009, 46:163-169.
25. Fatourechi M.M., Kudva Y.C., Murad M.H., Elamin M.B., Tabini C.C., Montori V.M. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009, 94:729-740.
26. Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14:iii-iv, xi-xvi, 1-181.
27. Gimenez M., Lara M., Conget I. Sustained efficacy of continuous subcutaneous insulin. Infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: A pilot study. Diabetes Technol Ther 2010, 12:517-521.
28. Schlichtkrull J., Munck O., Jersild M. The m-valve, an index of blood-sugar control in diabetics. Acta Med Scand 1965, 177:95-102.
29. Wójcicki J.M. Mathematical descriptions of the glucose control in diabetes therapy. Analysis of the Schlichtkrull " M" -value. Horm Metab Res 1995, 27:1-5.
30. Service F.J., Molnar G.D., Rosevear J.W., Ackerman E., Gatewood L.C., Taylor W.F. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970, 19:644-655.
31. Tai M.M. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 1994, 17:152-154.
32. Diabetes Treatment Satisfaction Questionnaire (DTSQ): change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care 1999;22:530-2.
33. Pickup J.C. Are insulin pumps underutilized in type 1 diabetes? Yes. Diabetes Care 2006, 29:1449-1452.
34. Warren E., Weatherley-Jones E., Chilcott J., Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004, 8:1-57.
35. Lepore M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vincenzo A. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine. NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000, 49:2142-2148.
36. Pickup J.C., Kidd J., Burmiston S., Yemane N. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev 2006, 22:232-237.
37. Kilpatrick E.S., Rigby A.S., Goode K., Atkin S.L. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007, 50:2553-2561.
38. Kim S.K., Suh S., Kim M.Y., Chung H.S., Hur K.Y., Kim S.W., et al. Three-day continuous glucose monitoring for rapid assessment of hypoglycemic events and glycemic variability in type 1 diabetic patients. Endocr J 2011, 58:535-541.
39. Hirsch I.B. Glycemic variability:it's not just about A1C anymore!. Diabetes Technol Ther 2005, 7:780-783.
40. Whitelaw B.C., Choudhary P., Hopkins D. Evaluating rate of change as an index of glycemic variability, using continuous glucose monitoring data. Diabetes Technol Ther 2011, 13:631-636.
41. Rodbard D. Glycemic variability: measurement and utility in clinical medicine and research--one viewpoint. Diabetes Technol Ther 2011, 13:1077-1080.
42. Simon B., Treat V., Marco C., Rosenberg D., Joseph J., Hipszer B. A comparison of glycaemic variability in CSII vs. MDI treated type 1 diabetic patients using CGMS. Int J Clin Pract 2008, 62:1858-1863.